171 related articles for article (PubMed ID: 38205741)
21. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
22. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
[TBL] [Abstract][Full Text] [Related]
23. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
Wilkinson S; Gupta A; Scheuer N; Mackay E; Arora P; Thorlund K; Wasiak R; Ray J; Ramagopalan S; Subbiah V
JAMA Netw Open; 2021 Oct; 4(10):e2126306. PubMed ID: 34618040
[TBL] [Abstract][Full Text] [Related]
24. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract][Full Text] [Related]
25. Assessing Techniques for Quantifying the Impact of Bias Due to an Unmeasured Confounder: An Applied Example.
Barberio J; Ahern TP; MacLehose RF; Collin LJ; Cronin-Fenton DP; Damkier P; Sørensen HT; Lash TL
Clin Epidemiol; 2021; 13():627-635. PubMed ID: 34349564
[TBL] [Abstract][Full Text] [Related]
26. Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966-1993.
Brundage MD; Mackillop WJ
J Clin Epidemiol; 1996 Feb; 49(2):183-92. PubMed ID: 8606319
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
28. Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms.
Burcu M; Dreyer NA; Franklin JM; Blum MD; Critchlow CW; Perfetto EM; Zhou W
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1228-1235. PubMed ID: 32162381
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
30. Exploring the Potential of External Control Arms created from Patient Level Data: A case study in non-small cell lung cancer.
Yin X; Mishra-Kalyan PS; Sridhara R; Stewart MD; Stuart EA; Davi RC
J Biopharm Stat; 2022 Jan; 32(1):204-218. PubMed ID: 34986069
[TBL] [Abstract][Full Text] [Related]
31. Real-World Data as External Controls: Practical Experience from Notable Marketing Applications of New Therapies.
Izem R; Buenconsejo J; Davi R; Luan JJ; Tracy L; Gamalo M
Ther Innov Regul Sci; 2022 Sep; 56(5):704-716. PubMed ID: 35676557
[TBL] [Abstract][Full Text] [Related]
32. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
Pasello G; Vicario G; Zustovich F; Oniga F; Gori S; Rosetti F; Bonetti A; Favaretto A; Toso S; Redelotti R; Santo A; Bernardi D; Giovanis P; Oliani C; Calvetti L; Gatti C; Palazzolo G; Baretta Z; Bortolami A; Bonanno L; Basso M; Menis J; Corte DD; Frega S; Guarneri V; Conte P;
Oncologist; 2019 Jun; 24(6):e318-e326. PubMed ID: 30846513
[TBL] [Abstract][Full Text] [Related]
33. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data.
Ton TGN; Pal N; Trinh H; Mahrus S; Bretscher MT; Machado RJM; Sadetsky N; Chaudhary N; Lu MW; Riely GJ
Clin Cancer Res; 2022 Jul; 28(13):2844-2853. PubMed ID: 35511917
[TBL] [Abstract][Full Text] [Related]
34. Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations.
Tan WK; Segal BD; Curtis MD; Baxi SS; Capra WB; Garrett-Mayer E; Hobbs BP; Hong DS; Hubbard RA; Zhu J; Sarkar S; Samant M
Contemp Clin Trials Commun; 2022 Dec; 30():101000. PubMed ID: 36186544
[TBL] [Abstract][Full Text] [Related]
35. Conditional borrowing external data to establish a hybrid control arm in randomized clinical trials.
Li H; Tiwari R; Li QH
J Biopharm Stat; 2022 Nov; 32(6):954-968. PubMed ID: 35067183
[TBL] [Abstract][Full Text] [Related]
36. External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning.
Loiseau N; Trichelair P; He M; Andreux M; Zaslavskiy M; Wainrib G; Blum MGB
BMC Med Res Methodol; 2022 Dec; 22(1):335. PubMed ID: 36577946
[TBL] [Abstract][Full Text] [Related]
37. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
[TBL] [Abstract][Full Text] [Related]
38. A systematic review of quantitative bias analysis applied to epidemiological research.
Petersen JM; Ranker LR; Barnard-Mayers R; MacLehose RF; Fox MP
Int J Epidemiol; 2021 Nov; 50(5):1708-1730. PubMed ID: 33880532
[TBL] [Abstract][Full Text] [Related]
39. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Lu S; Shih JY; Jang TW; Liam CK; Yu Y
Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
